title: Outcome results renew debate about diabetes drug development.
authors.forename: Asher
authors.initials: A
authors.lastname: Mullard
mesh_terms: D000218:Adamantane / Q000031:analogs & derivatives / Q000494:pharmacology; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D002986:Clinical Trials as Topic / Q000379:methods*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000188:drug therapy*; D004151:Dipeptides / Q000494:pharmacology; D017277:Drug Approval / Q000331:legislation & jurisprudence / Q000379:methods*; D006801:Humans; D007004:Hypoglycemic Agents / Q000592:standards* / Q000627:therapeutic use; D010880:Piperidines / Q000494:pharmacology; D016896:Treatment Outcome; D014498:Uracil / Q000031:analogs & derivatives / Q000494:pharmacology
chemical_list: D004151:Dipeptides; D007004:Hypoglycemic Agents; D010880:Piperidines; D014498:Uracil; C502994:saxagliptin; C520853:alogliptin; D000218:Adamantane